Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cigna Corp.

www.cigna.com

Latest From Cigna Corp.

Employers Would ‘Welcome’ Government Role In Covering High-Cost Therapies

Annual large employer health benefits survey for 2020 and beyond finds support for government price negotiation and payment through a national fund. Plans to expand point-of-sale rebates and coupon accumulator programs also reported.

Reimbursement Pricing Strategies

Opioid Blister Packs Need Study Before Mandate, Groups Urge

AAM, Upsher-Smith, APhA, and Cigna tell US FDA that packaging requirement will increase manufacturing and drug costs, create reimbursement hurdles and reduce access to medicines. Daiichi-Sankyo supports agency's proposal.

Drug Safety Neurology

PBM Integration: Economists Outline Benefits Of Mergers In Senate Hearing

Recent mergers between PBMs and insurers should address one long-term strategic objective of pharma – the recognition by payors of the value of biopharmaceutical products in relation to other medical costs.

Pharmacy Benefit Management M & A

It's Official: Novartis SMA Gene Therapy Zolgensma Is World's Most Expensive Drug

The total cost of Zolgensma is more than $2m – in line with estimates – or $425,000 annually for five years if payers choose an annuity-like payment plan. Novartis is also negotiating value-based reimbursement agreements for infants treated with the one-time infusion.

Approvals Gene Therapy
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register